During a follow-up period of median 12months, the rate of SR was significantly higher in patients with higher MHR levels (45% in tertile 1, 54% in tertile 2 and 62%in tertile 3, p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVE: Monocyte to high-density lipoprotein ratio (MHR) has recently been postulated as a novel parameter relatedto adverse cardiovascular outcomes.
📊
Key Findings & Data:In this study, we aimed to investigate the correlation of MHR with stent restenosis (SR)rates after the primary percutaneous coronary intervention (PCI) and bare-metal stent (BMS) implantation.METHODS: In this study, patients who had undergone primary PCI for STEMI and had a control angiogram during follow-upwere retrospectively recruited.
💡
Conclusion & Impact:During a follow-up period of median 12months, the rate of SR was significantly higher in patients with higher MHR levels (45% in tertile 1, 54% in tertile 2 and 62%in tertile 3, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
OBJECTIVE: Monocyte to high-density lipoprotein ratio (MHR) has recently been postulated as a novel parameter relatedto adverse cardiovascular outcomes. In this study, we aimed to investigate the correlation of MHR with stent restenosis (SR)rates after the primary percutaneous coronary intervention (PCI) and bare-metal stent (BMS) implantation.METHODS: In this study, patients who had undergone primary PCI for STEMI and had a control angiogram during follow-upwere retrospectively recruited. Patients were categorized according to admission MHR tertiles, clinical and angiographic datawere compared. In addition, predictors of SR were evaluated with logistic regression analysis.RESULTS: A total number of 448 patients (240 patients with SR and 208 patients without SR) were included in this study.Patients were categorized into three groups according to tertiles of admission MHR. During a follow-up period of median 12months, the rate of SR was significantly higher in patients with higher MHR levels (45% in tertile 1, 54% in tertile 2 and 62%in tertile 3, p
🔖
Cite This Article
KARATAŞ, M. B., SUNGUR, A., ŞAHİN, İ., KESKİN, M., KARADENİZ, F. Ö., ÇANGA, Y., GÜNGÖR, B., HAYIROĞLU, M. İ., AVCI, İ. İ., ÖZCAN, K. S. (2022). Association of monocyte to high-density lipoprotein ratio with bare-metal stent restenosis in STEMI patients treated with primary PCI. İstanbul Kuzey Klinikleri, Cilt: 6 - Sayı: 4, 393–400. https://ajindex.com/articles/652026
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003
13–20. [CrossRef ] 2. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010
1897–907. [CrossRef ] 3. Turak O, Canpolat U, Özcan F, Mendi MA, Oksüz F, Işleyen A, et al. Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Am J Cardiol 2014
197–202. [CrossRef ] 4. Turak O, Ozcan F, Isleyen A, Tok D, Sokmen E, Buyukkaya E, et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol 2012
1405–10. [CrossRef ] 5. Börekçi A, Gür M, Türkoğlu C, Selek S, Baykan AO, Seker T, et al. Oxidative Stress and Spontaneous Reperfusion of Infarct-Related Artery in Patients With ST-Segment Elevation Myocardial Infarction. Clin Appl Thromb Hemost 2016
171–7. [CrossRef ] 6. Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014
1619– 25. [CrossRef ] 7. Canpolat U, Çetin EH, Cetin S, Aydin S, Akboga MK, Yayla C, et al.Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation. Clin Appl Thromb Hemost 2016
476–82. [CrossRef ] 8. Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Çay S, et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015
1807–15. [CrossRef ] 9. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007
2344–51. [CrossRef ] 10. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med 2015
483–93. [CrossRef ] 11. Rasoul S, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Marcel Gosselink AT, et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009
415–21. [CrossRef ] 12. Makrygiannis SS, Ampartzidou OS, Zairis MN, Patsourakos NG, Pitsavos C. Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acu